Nuveen Asset Management LLC Sells 97,420 Shares of 908 Devices Inc. (NASDAQ:MASS)

Nuveen Asset Management LLC decreased its position in shares of 908 Devices Inc. (NASDAQ:MASS - Free Report) by 47.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 106,951 shares of the company's stock after selling 97,420 shares during the quarter. Nuveen Asset Management LLC owned 0.31% of 908 Devices worth $235,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Prudential Financial Inc. purchased a new position in shares of 908 Devices during the fourth quarter valued at approximately $34,000. Occudo Quantitative Strategies LP purchased a new stake in 908 Devices during the 4th quarter valued at $36,000. Hsbc Holdings PLC raised its stake in 908 Devices by 32.2% during the 4th quarter. Hsbc Holdings PLC now owns 21,007 shares of the company's stock valued at $46,000 after buying an additional 5,112 shares during the last quarter. Concurrent Investment Advisors LLC bought a new position in shares of 908 Devices during the 4th quarter valued at $52,000. Finally, Stifel Financial Corp bought a new position in shares of 908 Devices during the 4th quarter valued at $52,000. Institutional investors own 88.06% of the company's stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 908 Devices in a report on Saturday, May 24th. Two research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.33.

908 Devices Trading Up 1.7%

NASDAQ MASS traded up $0.12 during trading hours on Tuesday, hitting $7.10. 547,522 shares of the company's stock traded hands, compared to its average volume of 1,016,258. The business's fifty day moving average price is $5.16 and its two-hundred day moving average price is $3.60. The firm has a market capitalization of $254.61 million, a P/E ratio of -4.01 and a beta of 0.29. 908 Devices Inc. has a 52 week low of $1.81 and a 52 week high of $7.32.

908 Devices (NASDAQ:MASS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.05. The firm had revenue of $11.78 million during the quarter, compared to the consensus estimate of $11.90 million. 908 Devices had a negative net margin of 109.11% and a negative return on equity of 24.60%. On average, sell-side analysts expect that 908 Devices Inc. will post -1.99 EPS for the current fiscal year.

Insider Buying and Selling at 908 Devices

In other news, Director Mark Spoto acquired 10,000 shares of 908 Devices stock in a transaction dated Wednesday, May 14th. The stock was purchased at an average cost of $4.29 per share, with a total value of $42,900.00. Following the completion of the purchase, the director now directly owns 62,971 shares in the company, valued at approximately $270,145.59. This trade represents a 18.88% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Joseph H. Iv Griffith sold 6,940 shares of 908 Devices stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $7.08, for a total transaction of $49,135.20. Following the transaction, the chief financial officer now owns 102,930 shares in the company, valued at approximately $728,744.40. This trade represents a 6.32% decrease in their position. The disclosure for this sale can be found here. 23.70% of the stock is currently owned by corporate insiders.

908 Devices Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.